Comparative Pharmacology
Head-to-head clinical analysis: PFIZERPEN VK versus PFIZERPEN A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PFIZERPEN VK versus PFIZERPEN A.
PFIZERPEN VK vs PFIZERPEN-A
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Penicillin V binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking, leading to cell lysis via autolytic enzymes.
Penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and activating autolytic enzymes.
Treatment of mild to moderate infections caused by susceptible gram-positive cocci (e.g., Streptococcus pyogenes, Streptococcus pneumoniae, susceptible staphylococci)Prophylaxis of rheumatic fever recurrenceOff-label: Treatment of erysipeloid, anthrax (cutaneous, post-exposure), clostridial infectionsOff-label: Periodontal infections (in combination with metronidazole)
Serious infections caused by susceptible gram-positive aerobes and anaerobes (e.g., streptococcal, meningococcal, clostridial)Syphilis (Treponema pallidum)ActinomycosisProphylaxis of rheumatic fever and bacterial endocarditisOff-label: Group B streptococcal infection in neonates, Lyme disease
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections. For group A streptococcal pharyngitis: 250 mg orally 3 times daily or 500 mg twice daily for 10 days.
1-2 million units intramuscularly or intravenously every 4 hours; or continuous intravenous infusion of 20-30 million units per day.
None Documented
None Documented
Terminal half-life: 30–60 minutes in adults with normal renal function; prolonged in renal impairment (up to 4–10 hours in anuria).
Terminal elimination half-life: 0.6-0.8 hours in adults with normal renal function; prolonged to 7-10 hours in end-stage renal disease (ESRD). In neonates, half-life ranges 2-4 hours.
Primarily excreted unchanged in urine via renal tubular secretion; minor hepatic metabolism to inactive metabolites (penicilloic acid).
Primarily renal tubular secretion (90% unchanged). Minimal hepatic metabolism.
Renal: ~60-80% unchanged via tubular secretion; biliary/fecal: minor (hepatic elimination of metabolites).
Primarily renal (60-70% unchanged via glomerular filtration and tubular secretion); hepatic metabolism minor (<10%); biliary/fecal elimination <10%.
~80% bound, primarily to serum albumin.
Approximately 60-65% bound primarily to serum albumin, with minor binding to alpha-1-acid glycoprotein.
0.3–0.5 L/kg (approx. 20–40 L in adults); limited distribution into CNS except with inflamed meninges.
0.2-0.3 L/kg; low Vd reflects limited tissue distribution (primarily extracellular fluid). Higher in neonates (0.4-0.5 L/kg).
Oral: approximately 60–75% (variable, reduced by food); IM: nearly complete (~100%).
Oral bioavailability: negligible (<10%) due to acid lability; IM bioavailability: ~80-100% with rapid absorption.
CrCl >30 mL/min: no adjustment. CrCl 10-30 mL/min: administer every 8-12 hours. CrCl <10 mL/min: administer every 12-18 hours. For anuria: avoid use or reduce dose to 250 mg every 12 hours.
For GFR 10-50 mL/min: administer every 6-8 hours. For GFR <10 mL/min: administer every 12 hours or reduce dose by 50%.
No specific Child-Pugh based adjustments required; monitor for hepatic adverse effects. No dose modification recommended in hepatic impairment.
No specific adjustment required; caution in severe hepatic impairment due to potential risk of encephalopathy.
Children >12 years: adult dosing. Infants and children <12 years: 25-50 mg/kg/day orally divided every 6-8 hours; maximum 3 g/day. For group A streptococcal pharyngitis: 25-50 mg/kg/day divided every 12 hours for 10 days.
Neonates <7 days: 50,000 units/kg intramuscularly or intravenously every 12 hours. Neonates 7-28 days: 50,000 units/kg every 8 hours. Infants and children: 100,000-250,000 units/kg/day divided every 4-6 hours.
No specific dose adjustment; use with caution due to age-related renal decline. Monitor renal function and adjust based on CrCl. Increased risk of adverse effects (e.g., seizures with high doses).
Use with caution; adjust dosing interval based on renal function; monitor for electrolyte disturbances.
No FDA black box warning.
None listed by FDA for this formulation; however, rapid IV administration may cause severe or fatal anaphylaxis. No specific boxed warning.
["Serious hypersensitivity reactions (anaphylaxis) may occur, especially in patients with penicillin allergy","Use caution in renal impairment (CrCl <10 mL/min) due to risk of neurotoxicity with high doses","Pseudomembranous colitis associated with C. difficile may occur","Prolonged use may predispose to superinfection","Assess renal function periodically in prolonged therapy"]
Hypersensitivity reactions (anaphylaxis) can occur; skin testing recommended in patients with penicillin allergy history. Neurologic adverse effects (e.g., seizures) with high doses or renal impairment. Electrolyte disturbances with large IV doses (potassium or sodium salt). Prolonged use may lead to superinfection due to Clostridium difficile.
["Hypersensitivity to penicillins or any component of the formulation","Previous history of immediate hypersensitivity reaction (e.g., anaphylaxis, Stevens-Johnson syndrome) to beta-lactams"]
Known hypersensitivity to penicillins. Use with caution in patients with history of severe immediate allergy to cephalosporins or carbapenems (possible cross-sensitivity).
Data Pending Review
Data Pending Review
Avoid taking with food, especially high-fiber or high-fat meals, as they reduce absorption. Avoid acidic beverages (e.g., fruit juices, colas) which may degrade the drug. Take with a full glass of water.
No significant food interactions; may be taken with or without food. Avoid alcohol to reduce risk of disulfiram-like reaction (rare).
Penicillin VK (phenoxymethylpenicillin) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and no adequate human studies exist for first trimester. However, penicillin VK is considered safe throughout pregnancy when clinically indicated. No known teratogenicity. Risk of neonatal coagulopathy if maternal administration near term due to gut flora alteration, but not directly teratogenic.
Penzicillin G (PFIZERPEN-A) is generally considered low risk in pregnancy. Animal studies have not shown teratogenicity. In humans, no increased risk of major congenital malformations has been observed. Use in the first trimester: no evidence of teratogenic effects. Second and third trimesters: no specific fetal risks, but may cause altered fetal gut flora. High doses near term may increase risk of kernicterus in jaundiced neonates.
Penicillin VK is excreted into breast milk in small amounts (M/P ratio approximately 0.1-0.2). Levels are unlikely to cause adverse effects in the infant. Risk of diarrhea, candidiasis, or allergic sensitization. Considered compatible with breastfeeding by the American Academy of Pediatrics.
Penicillin G is excreted into breast milk in low concentrations. The milk-to-plasma ratio is approximately 0.2. Doses up to 1.2 million units daily are considered compatible with breastfeeding. Theoretical risk of alteration of infant gut flora and sensitization. Monitor infant for rash and gastrointestinal disturbances.
No dose adjustment typically required in pregnancy. However, increased plasma volume and renal clearance may slightly reduce serum levels, but clinical significance is minimal. Standard dosing is adequate for most pregnant patients. For severe infections, consider higher doses if necessary.
Pregnancy increases volume of distribution and renal clearance of penicillin G, leading to lower serum concentrations. Dose adjustments may be necessary, especially in the third trimester. Increased dosing frequency or higher doses may be required for serious infections. Monitor clinical response and consider therapeutic drug monitoring when available.
Category C
Category C
PFIZERPEN VK (penicillin V potassium) is a narrow-spectrum penicillinase-sensitive penicillin. It is the drug of choice for group A streptococcal pharyngitis and for prophylaxis of rheumatic fever. It is acid-stable and can be given orally, but absorption is impaired by food. Dosing should be adjusted for renal impairment (CrCl <10 mL/min, dose every 12 hours). It has poor activity against H. influenzae and is not reliable for serious staphylococcal infections. Allergy cross-reactivity with cephalosporins is rare but possible.
Administration with penicillin skin testing recommended prior to therapy; monitor for immediate hypersensitivity reactions; adjust dose in renal impairment (CrCl <10 mL/min) to q12h; preferred for neurosyphilis due to high CNS penetration; use with probenecid to increase serum levels; check for cross-reactivity in patients with cephalosporin allergy; reconstitute with sterile water for injection; avoid IM injection in neonates due to risk of sterile abscess; maintain adequate hydration to prevent crystalluria with high doses.
Take on an empty stomach (1 hour before or 2 hours after meals) for best absorption.Complete the full course even if you feel better to prevent resistance.If a dose is missed, take it as soon as possible; if near next dose, skip the missed dose. Do not double dose.Common side effects include nausea, vomiting, diarrhea, and rash. Contact doctor if severe diarrhea or allergic symptoms occur.Do not take with acidic beverages like fruit juices or sodas; take with water.Inform clinician about any kidney disease or history of allergies.
Complete the full course of therapy even if you feel better.Report any skin rash, hives, difficulty breathing, or swelling immediately.Take with food if gastrointestinal upset occurs.Avoid alcohol while on treatment.Inform your doctor if you have kidney disease or are pregnant.Store oral suspension in refrigerator; discard after 14 days.Do not skip doses; take at evenly spaced intervals.